Browse by author
Lookup NU author(s): Dr Tetsushi Kataura, Professor Viktor KorolchukORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2026 The Authors.Lack of DNA double-strand break repair efficiency exquisitely sensitizes cancers to poly-ADP ribose polymerase inhibitors (PARPi). Unfortunately, resistance to PARPi poses an insurmountable challenge for patients. Mechanisms that confer insensitivity to PARPi therapy include enhanced DNA damage repair and autophagy. Natural and non-natural unsaturated fatty acid nitroalkene derivatives (NFA) show anticancer actions that sensitize TNBC cells to PARPi and other DNA-damaging treatments. We reveal that nitro-oleic acid (OA-NO2) re-sensitizes PARPi-resistant TNBC cells to PARPi. RNA-seq analysis of clinically relevant mutBRCA1 PARPi-resistant TNBC cell lines exhibited upregulation in autophagy and lysosomal pathways. Bio-orthogonal analysis identified the autophagy regulator SQSTM1/p62 as a novel OA-NO2 target, alkylating two redox-sensitive Cys residues of p62 (Cys105 and Cys113). These Cys are essential for p62 regulation of autophagy and mimicked the effects of p62 Cys105 and Cys113Ala mutants and when alkylated by OA-NO2 showed impaired p62 oligomerization, degradation, and inhibition of autophagy. Combination treatment of PARPi-resistant TNBC with a PARPi and OA-NO2 identified the most synergistic HSA scores and inhibited p62-associated autophagy and lysosome function. These data underscore the clinical potential of OA-NO2 for treating PARPi-resistant TNBC patients.
Author(s): Hong L, Lee S, Frisbie L, Zhao Y, Skoko JJ, Merkel C, Kataura T, Korolchuk VI, Coffman LG, Lee AV, Freeman BA, Schopfer FJ, Neumann CA
Publication type: Article
Publication status: Published
Journal: Cancer Letters
Year: 2026
Volume: 651
Print publication date: 28/07/2026
Online publication date: 12/04/2026
Acceptance date: 11/04/2026
ISSN (print): 0304-3835
ISSN (electronic): 1872-7980
Publisher: Elsevier Ireland Ltd
URL: https://doi.org/10.1016/j.canlet.2026.218504
DOI: 10.1016/j.canlet.2026.218504
PubMed id: 41974247
Altmetrics provided by Altmetric
